Treatments & Interventions
Research Evidence
Peer-reviewed studies linked via MeSH term "Lymphoma, Mantle-Cell" from the MEDLINE/PubMed database.
Sort:
Chimeric antigen receptor T-cell therapy in relapsed or refractory mantle cell lymphoma: a systematic review and meta-analysis.
[object Object], [object Object], [object Object] et al. · Front Immunol · 2024
Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis.
[object Object], [object Object], [object Object] et al. · Leuk Lymphoma · 2024
PMID: 38975903Meta-Analysis
Long non-coding RNA as a novel biomarker and therapeutic target in aggressive B-cell non-Hodgkin lymphoma: A systematic review.
[object Object], [object Object] · J Cell Mol Med · 2023
Unveiling the Prognostic Significance of BCL6+/CD10+ Mantle Cell Lymphoma: Meta-Analysis of Individual Patients and Systematic Review.
[object Object], [object Object], [object Object] et al. · Int J Mol Sci · 2023
Assessing the diagnosis of "primary cutaneous mantle cell lymphoma": A systematic review and population-based analysis.
[object Object], [object Object], [object Object] et al. · J Am Acad Dermatol · 2022
PMID: 34343606Meta-Analysis
Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials.
[object Object], [object Object], [object Object] et al. · Front Immunol · 2022
Effectiveness of Bendamustine-Rituximab Compared to R-CHOP/R-CVP as a First-Line Treatment of Indolent Non-Hodgkin's Lymphoma or Mantle-Cell Lymphoma.
[object Object], [object Object] · Acta Med Indones · 2022
PMID: 35818660Meta-Analysis
Efficacy and safety of ibrutinib in mantle cell lymphoma: A systematic review and meta-analysis.
[object Object], [object Object], [object Object] et al. · Daru · 2022
Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: A systematic literature review.
[object Object], [object Object], [object Object] et al. · Crit Rev Oncol Hematol · 2021
PMID: 33383209Meta-Analysis
Association of minimal residual disease levels with clinical outcomes in patients with mantle cell lymphoma: A meta-analysis.
[object Object], [object Object], [object Object] et al. · Leuk Res · 2021
PMID: 34090063Meta-Analysis
Search all PubMed articles for Mantle cell lymphoma
Research data from MEDLINE/PubMed
Signs & Symptoms
Based on Human Phenotype Ontology (HPO) disease-phenotype annotations.
B-cell lymphoma
Very frequent (80-99%)HP:0012191
Swollen lymph nodes
Very frequent (80-99%)HP:0002716
Anomaly of the bone marrow cells
Frequent (30-79%)HP:0005561
Anorexia
Frequent (30-79%)HP:0002039
Large spleen
Frequent (30-79%)HP:0001744
Pyrexia
Frequent (30-79%)HP:0001945
Tiredness
Frequent (30-79%)HP:0012378
Weight loss
Frequent (30-79%)HP:0001824
Gastrointestinal disease
Occasional (5-29%)HP:0011024
Quick Facts
- SNOMED CT
- 443487006
- UMLS CUI
- C4721414
- Fully Specified Name
- Mantle cell lymphoma (disorder)
- Specialists
- 0
- Diagnostic Biomarkers
- 0
- HPO Phenotypes
- 9
- Known Treatments
- 8
Medical Disclaimer
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Clinical content is derived from the SNOMED CT clinical ontology and curated medical knowledge graphs.